<DOC>
	<DOC>NCT00134264</DOC>
	<brief_summary>The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents</brief_summary>
	<brief_title>A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Diagnosis of coronary heart disease or risk equivalents that place the patient at high risk for cardiovascular disease events Women who are pregnant or lactating, or planning to become pregnant. Subjects with a clinically indicated need for statin (HMGCoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDLC and HDLC including fibrates and nicotinic acid Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMGCoA reductase inhibitors Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>